共 186 条
[1]
Selvin E.(2008)Cardiovascular outcomes in trials of oral diabetes medications: a systematic review Arch Intern Med 168 2070-80
[2]
Bolen S.(2007)Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457-71
[3]
Yeh H.C.(2007)Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180-8
[4]
Nissen S.E.(2007)Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 1189-95
[5]
Wolski K.(2007)Congestive heart failure and cardiovascular death in patients with pre-diabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials Lancet 370 1129-36
[6]
Lincoff A.M.(2007)Thiazolidinediones and the risk of edema: A meta-analysis Diabetes Res Clin Pract 76 279-89
[7]
Wolski K.(2007)Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies Drug Saf 30 741-53
[8]
Nicholls S.J.(2008)Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes Metab 10 312-28
[9]
Singh S.(2002)A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes Diabetes Care 25 2058-64
[10]
Loke T.K.(1974)Role of diabetes in congestive heart failure: the Framingham Study Am J Cardiol 34 29-34